ClearView runs candidate-led life-sciences cases plus a separate science discussion built around your own scientific background. Expect roughly 2 to 3 rounds and a fit interview. The case is a classic structure applied to a life-sciences problem, around 30 minutes. The science round is what candidates consistently name as the hardest and most distinctive part of the loop.
What ClearView is, in one line
ClearView is a life-sciences-only boutique advising pharma, biotech, medical device and diagnostics clients across the product lifecycle. Its center of gravity is early strategy: pipeline and portfolio prioritization, therapeutic-area and platform investment decisions, and licensing and partnership assessment, alongside launch and market access.
The culture is science-dense. Publicly reported figures put more than half of consultants as holders of a life-sciences PhD. That single fact explains most of what follows about the interview.
ClearView expects you to reason about the biology, not just the business.
The interview format
Expect roughly 2 to 3 rounds plus a fit interview. A first-round case applies a classic structure to a life-sciences problem, usually around 30 minutes. The final round typically splits into two parts: a behavioral and situational interview, and a separate science discussion built around your own area of scientific interest and background.
Cases are largely candidate-led. You drive the structure and the analysis, and nobody is going to hand you the next step. Public difficulty reads around 3 out of 5, which understates it slightly, because the difficulty is not concentrated in the case math.
The science interview is the signature
This is what separates ClearView from every generalist firm and from most of its life-sciences peers. You may be asked to break down a technical scientific problem and reason through it out loud.
The point is not trivia. Nobody is checking whether you remember a pathway diagram. The point is whether you have real scientific fluency: whether you can hold a mechanism in your head, reason about why an approach might work, and say honestly why it might fail.
Prepare to talk with confidence about the science in your own background. Mechanism, trial design, and the case for and against a given approach.
If your background is not technical
The question flexes rather than disappears. You may instead be asked to explain a scientific advancement you find interesting and why it matters. The bar does not move: you still have to demonstrate that you can understand and reason about science.
The practical move is to pick one advance you genuinely follow, not one you think sounds impressive, and be able to explain four things about it. What it does. Why it is a step forward. What is still unsolved. And what would have to be true for it to fail.
The science question can land in any round, not just the final one. It depends on the interviewer. Be ready for it throughout the loop rather than saving your preparation for the last day.
How the loop shifts by track
Round count and depth move by level. Directionally, and confirm your own loop:
| Track | What the loop emphasizes |
|---|---|
| Analyst / undergrad | Typically fewer rounds. The case tests structure and quantitative comfort more than deep domain knowledge. |
| Associate consultant / experienced hire | More cases, and a higher bar on synthesis and landing a clear recommendation. |
| MBA or PhD associate | The science discussion carries more weight. You are expected to bring genuine domain depth. |
The archetypes they favor
Pipeline and portfolio prioritization. Therapeutic-area or platform investment decisions. Business development and licensing valuation. Product launch. And market sizing built from diagnosis and treatment rates rather than handed to you as a number.
The through-line across all of them is a scientific judgment call sitting underneath the business question. That is the pattern to train on.
A ClearView-flavored prompt to drill
"A biotech client has three early-stage assets, each hitting a different biological target in a different disease area, and only enough capital to advance one into a full development program. Leadership wants to know which asset to prioritize, and why. As part of your answer, walk me through how you would judge whether the underlying biology of each asset is strong enough to bet on."
What a strong candidate does. Build a prioritization scorecard first: unmet need, mechanistic rationale and proof of concept, market size, competition, development cost and time, strategic fit. That much is table stakes and a good generalist gets there.
Then actually engage the science branch. Do not treat "mechanistic rationale" as a box to tick on the way to the market-size number. Say what evidence would make you believe the target is real. Human genetic validation. A translatable animal model. Early clinical proof of mechanism in the right patient population. Say what would make you walk away: a target that has failed repeatedly in the clinic for reasons nobody has explained, or a mechanism that only works in a model that does not translate.
That second move is the ClearView tell. Candidates who build a clean scorecard and then race past the biology to the sizing math get a competent score. Candidates who slow down on the science branch get the offer.
A two-week prep sequence
- Pick your science story and rehearse it out loud. One mechanism you know cold, explained in four minutes: what it does, why it is a step forward, what is unsolved, what would falsify it. Say it to a wall until it stops sounding rehearsed.
- Drill portfolio prioritization, not profitability. Generic case books push you toward profitability and market entry. ClearView is asking you to choose between assets under capital constraint. Different structure, different muscle.
- Build one therapeutic-area primer. If your background is thin in an area ClearView is known for, spend an afternoon on a one-pager: the disease, the standard of care, what the current unmet need actually is, who the players are.
- Practice sizing from diagnosis and treatment rates. Not from a given market number. The funnel is the skill.
- Rehearse the recommendation. Candidate-led means nobody prompts you to conclude. You have to decide when the analysis is done and then say the answer out loud with a reason attached.
Go deeper
Work 5 life-sciences cases free
Five prompts across drugs, devices, diagnostics and digital health, plus the patient funnel framework. No email gate on the content, no upsell buried in it. Work them cold before you look at the hints.